Search Within

Komal Lachhman Jhaveri

Formats
  1. Meeting Abstract (120)
  2. Journal Article (89)
  3. Review (7)
  4. Editorial (2)
  5. Correspondence (1)
  6. Guidelines (1)
Groups
  1. Breast Medicine Service (220)
  2. Department of Medicine (220)
  3. Solid Tumor Oncology Division (220)
  4. GSK Faculty (58)
  5. Survivorship Research (47)
  6. Epidemiology and Biostatistics (44)

More Groups

People
  1. Shanu Modi (35)
  2. Sarat Chandarlapaty (28)
  3. Pedram Razavi (25)
  4. Clifford Hudis (24)
  5. Sujata Patil (22)
  6. Gary Ulaner (18)

More People

Years
  1. 2025 (26)
  2. 2024 (34)
  3. 2023 (17)
  4. 2022 (24)
  5. 2021 (26)
  6. 2020 (28)

More Years

Publications
  1. Journal of Clinical Oncology (66)
  2. Cancer Research (33)
  3. Annals of Oncology (22)
  4. Clinical Cancer Research (10)
  5. European Journal of Cancer (5)
  6. New England Journal of Medicine (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (69)
  2. American Association for Cancer Research (47)
  3. Oxford University Press (23)
  4. Elsevier Inc. (18)
  5. Springer (7)
  6. Nature Publishing Group (6)

More Publishers

Results (220)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Abemaciclib in combination with endocrine therapy for patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A phase 1b study
    Journal Article

    Tolaney, S. M.; Beeram, M.; Beck, J. T.; Conlin, A.; Dees, E. C.; Puhalla, S. L.; Rexer, B. N.; Burris, H. A. 3rd; Jhaveri, K.; Helsten, T.; more...
    Frontiers in Oncology (2022)

    Fulltext@MSK | Save
  • A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study
    Meeting Abstract

    Jhaveri, K. L.; Lim, E.; Hamilton, E. P.; Saura, C.; Meniawy, T.; Jeselsohn, R.; Beck, J. T.; Kaufman, P. A.; Sammons, S.; Banda, K.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC)
    Meeting Abstract

    Jhaveri, K. L.; Boni, V.; Sohn, J.; Villanueva-Vásquez, R.; Bardia, A.; Schmid, P.; Lim, E.; Patel, J. M.; Perez-Fidalgo, J. A.; Loi, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) operable breast cancer (BC)
    Meeting Abstract

    Moore, H. M.; Boni, V.; Bellet, M.; De Las Heras, B. B.; Cortés, M. G.; Oakman, C.; Schmid, P.; Trinh, X. B.; Wheatley, D.; Jhaveri, K. L.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase 1A clinical trial of the first-in-class fascin inhibitor NP-G2-044 evaluating safety and anti-tumor activity in patients with advanced and metastatic solid tumors
    Meeting Abstract

    Chung, V.; Jhaveri, K. L.; Von Hoff, D. D.; Huang, X. Y.; Garmey, E. G.; Zhang, J.; Tsai, F. Y. C.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Clinical and morphologic characteristics of fibroblast growth factor receptor inhibitor-associated retinopathy
    Journal Article

    Francis, J. H.; Harding, J. J.; Schram, A. M.; Canestraro, J.; Haggag-Lindgren, D.; Heinemann, M.; Kriplani, A.; Jhaveri, K.; Voss, M. H.; Bajorin, D.; more...
    JAMA Ophthalmology (2021)

    Fulltext@MSK | Save
  • A phase I study of LSZ102, an oral selective estrogen receptor degrader, with or without ribociclib or alpelisib, in patients with estrogen receptor-positive breast cancer
    Journal Article

    Jhaveri, K.; Juric, D.; Yap, Y. S.; Cresta, S.; Layman, R. M.; Duhoux, F. P.; Terret, C.; Takahashi, S.; Huober, J.; Kundamal, N.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • The evolution of cyclin dependent kinase inhibitors in the treatment of cancer
    Journal Article

    Jhaveri, K.; Burris, H. A. 3rd; Yap, T. A.; Hamilton, E.; Rugo, H. S.; Goldman, J. W.; Dann, S.; Liu, F.; Wong, G. Y.; Krupka, H.; more...
    Expert Review of Anticancer Therapy (2021)

    Fulltext@MSK | Save
  • Monitoring circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) genomic alterations in ER positive (POS)/HER2 negative (NEG) advanced breast cancer during endocrine therapy: Correlative study of AZD9496 oral SERD phase I trial
    Meeting Abstract

    Cani, A. K.; Dolce, E. M.; Darga, E. P.; Hu, K.; Brown, M.; Liu, C. J.; Pierce, J.; Bradbury, K.; Aung, K.; Schiavon, G.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging
    Journal Article

    Morikawa, A.; Grkovski, M.; Patil, S.; Jhaveri, K. L.; Tang, K.; Humm, J. L.; Holodny, A.; Beal, K.; Schöder, H.; Seidman, A. D.
    Breast Cancer Research and Treatment (2021)

    Fulltext@MSK | Save